Lyfegen raises CHF 750‘000 in Seed Capital

The complexity of drug rebate management has grown significantly in recent years. With multiple rebate structures, evolving regulations, and limited visibility across the process, pharmaceutical companies and payers face increasing challenges in tracking, optimizing, and ensuring compliance in rebate agreements.

Traditional rebate management often relies on manual processes, spreadsheets, and siloed data sources—leading to inefficiencies, errors, and revenue leakage. But technology is changing that. Automation, real-time analytics, and centralized platforms are transforming how pharma and payers approach rebate strategies.

The Role of Technology in Rebate Optimization

Automation and AI

• Eliminate manual data entry and reduce administrative workload
• Enable real-time rebate tracking and forecasting for greater accuracy

Advanced Analytics and Predictive Modeling

• Identify trends in rebate performance to shape better contracts
• Enhance revenue predictability and inform smarter financial planning

Improved Compliance & Transparency

• Align rebate operations with global regulatory requirements
• Provide audit-ready reporting to reduce compliance risks

A Smarter Way Forward with Lyfegen

The future of rebate management isn’t manual—it’s intelligent, automated, and built for scale. That’s exactly where Lyfegen comes in.

Our Rebate Analytics Platform is designed to help both payers and pharmaceutical companies take control of growing complexity. With automation, analytics, and real-time insights at its core, Lyfegen enables your team to:

• Track rebates effortlessly through a centralized, digital-first platform
• Uncover missed revenue opportunities with clear, data-driven insights
• Stay compliant with evolving regulatory requirements and audit-ready reporting
• Move faster and smarter, eliminating the risks of spreadsheets and disconnected systems

Let’s make rebates work for you—not against you.

Payers and pharma leaders around the world are already using Lyfegen to recover lost revenue and gain full visibility into their rebate performance.

Now it’s your turn. 👉 Book a demo and see how Lyfegen transforms rebate management—starting today.

‍

With price tags in the millions, gene therapies are redefining medicine—and reshaping how we negotiate access to it. For both payers and pharmaceutical companies, these breakthrough treatments present a shared challenge: how do you fund what feels priceless?

From Zolgensma to Hemgenix, gene therapies promise one-time cures for rare and life-threatening diseases. But the financial model behind them can’t follow the traditional playbook. These treatments call for a smarter, more collaborative approach to pricing—and that’s exactly what’s taking root.

Why Payers and Pharma Need a New Playbook

Unlike conventional drugs, gene therapies frontload their cost while delivering benefits over time. That disconnect forces a fundamental rethink of how pricing, reimbursement, and risk-sharing are handled.

According to the Lyfegen 2024 Drug Contracting Trends Report, health systems worldwide are moving toward innovative agreements: outcome guarantees, installment plans, and subscription-based models. These aren’t just experiments—they’re becoming essential tools to balance patient access with financial responsibility.

For payers, it’s about managing risk while maintaining equity. For pharma, it’s about demonstrating value in a way that aligns with clinical reality. Either way, the direction is clear: shared risk, shared benefit.

Global Shifts That Are Shaping the Market

The trends are global and accelerating. In the United States, payers like Blue Cross Blue Shield and Medicaid are embracing outcome-based models for sickle cell gene therapies like Casgevy and Lyfgenia. Brazil’s Ministry of Health uses installment payments for Zolgensma, spreading risk over five years while tying reimbursement to real-world outcomes.

In Europe, countries like Spain and Italy combine restricted coverage with annual reassessments, ensuring that high-cost therapies are only reimbursed if they continue to deliver results.

The message? Pricing innovation is no longer a nice-to-have—it’s the only way forward.

How Lyfegen Bridges the Gap

At Lyfegen, we help payers and pharma move beyond the negotiation table—and into action.

• Our Agreements Library, the world’s largest digital repository of value-based contracts, helps you understand what others are doing and where the benchmarks lie.

• Our pricing simulation engine lets both sides explore scenarios before committing—making deals smarter from day one.

• And our automated platform handles everything from contract setup to rebate tracking, saving time, reducing risk, and driving transparency.

A Smarter Way to Fund the Future of Medicine

Gene therapies will continue to challenge the limits of what we think healthcare can afford. But with the right models and tools, both payers and pharma can find common ground—ensuring that innovation reaches the patients who need it most.

Curious about what’s next in drug contracting?

Download the 2024 Drug Contracting Trends Report for exclusive insights, real-world examples, and global benchmarks.

👉 Get the full report now

‍